A Phase 1 Open Label Dose Escalation Trial of QPI-1007 D

Project: Research project

Project Details

Description

A Pahse 1 Open Label Dose Escalation Trial of QPI-1007 Delivered by Single Intravitreal Injection to Patients with Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Optic Neuropathy (NAJON) (Stratum II)
StatusFinished
Effective start/end date2/15/102/14/13

Funding

  • Quark Pharmaceuticals, Inc.

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.